Outcomes of different treatments for patients with advanced hepatocellular carcinoma: a single center retrospective study / 中华肝胆外科杂志

ABSTRACT

Objective To analyze the outcomes of different treatments in 126 patients with advanced hepatocellular carcinoma (HCC).Methods The follow-up data of 126 BCLC-B or C stage HCC patients who received different treatments were retrospectively studied.These patients were divided into six groups according to the treatment.Group 1untreated; Group 2TACE only; Group 3TACE + Sorafenib;Group 4liver resection ; Group 5liver resection + TACE; Group 6liver resection + TACE + Sorafenib.The survival times were analyzed using Kaplan-Meier method and the results were analyzed using the log-rank test.Results Among the non-surgery groups,the 1 year survival rate in Group 3 (62.5％,medium survival 16 months) was longer than Groups 1 and 2.For patients in the liver resection groups,the 1 year and overall survival rates were much better than the non-surgery groups.There were no significant differences in 1 year and 2 year survivals among Groups 4,5,and 6.However,the 3 year survival rate in Group 6 was much longer than Groups 4 and 5.The medium survival in Groups 4,5,and 6 were 24,24.5,and 28 months,respectively.Moreover,the medium survivals after post-hepatectomy recurrence in Groups 4,5 and 6 were 7,9.5,and 18 months,respectively.Sorafenib significantly prolonged survival after HCC recurrence.Conclusions Liver resection was still the best and the most effective treatment for patients with advanced HCC.Combining TACE with Sorafenib was a better treatment for patients with non-resectable HCC.Sorafenib effectively inhibited progression of post-hepatectomy HCC recurrence and significantly prolonged survival.Therefore,Sorafenib is a good approach in the prevention and treatment of HCC recurrence.